Gubra
Gubra A/S is a Danish biotechnology company specialized in contract research services and peptide-based drug discovery for metabolic disorders. The company operates two main business segments, providing high-throughput preclinical contract research services alongside discovering proprietary target compounds in obesity and kidney disease. Main revenue drivers include fee-for-service preclinical research testing for external biopharmaceutical firms, milestone payments, and drug licensing partnerships. Gubra serves global pharmaceutical corporations, biotechnology developers, and academic research institutions across Europe, North America, and Asia. The company holds a specialized market position in preclinical metabolic disease research and automated peptide discovery. Headquartered in Horsholm, Denmark, Gubra A/S is listed on Nasdaq Copenhagen.
8 of the funds FundTelligence covers report a position in Gubra.
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 8
- Exposure themes
- Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health
Funds holding Gubra
- Schroder ISF Nordic Smaller Companies — Schroders · 0.85 % (full portfolio disclosed, June 2026)
- KLP AksjeNorden Mer Samfunnsansvar — KLP · 0.22 % (full portfolio disclosed, June 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.1 % (full portfolio disclosed, October 2026)
- Nordea Nordic Small Cap Fund — Nordea Funds · 0.04 % (full portfolio disclosed, July 2026)
- Nordea Nordic Small Cap — Nordea Funds · 0.04 % (full portfolio disclosed, July 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeNorden Indeks — KLP · 0.02 % (full portfolio disclosed, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)